Zusammenfassung
Die antihyperglykämische Therapie ist in der Behandlung des Diabetikers von zentraler Bedeutung. Im folgenden Artikel werden die antidiabetischen Therapieformen unter besonderer Berücksichtigung älterer Patienten zusammengefasst.
Summary
The control of glycemia is of central importance in the therapy of patients with type 2 diabetes. This article summarizes the treatment options with respect to oral antidiabetic medication and with special consideration of elderly patients.
This is a preview of subscription content, log in via an institution to check access.
References
UKPDS: Effect of intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complicationsin patients with type 2 diabetes (UKPDS33), UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352: 837–853, 1998
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependet diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract, 28: 103–117, 1995
Duckworth W, Abaira C, Moritz T, et al.; for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 360: 129–139, 2009
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 358: 2545–2559, 2008
The ADVANCE Collaborative Group – Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 358: 2560–2571, 2008
Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association, European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustement of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32: 193–203, 2009
European Union Geriatrics Medicine Society (EUGMS) Clinical guidelines for type 2 diabetes mellitus in the eldery. 2004 (Download: www.eugms.org)
Clodi M, Fasching P, Hoppichler F, et al. Antidiabetische therapie bei typ 2 diabetes. Wien Klin Wochenschr, 121(Suppl. 5): S13–S17, 2009
Bosi E. Metformin – the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab, 11(Suppl. 2): S3–S8, 2009
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352: 854–865, 1998
Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacolgical treatment of insulin resistance in high-risk hispanic women. Diabetes, 51: 2796–2803, 2005
Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism, 60: 1–23, 2011
Dormandy JA, Charbonnel E, Eckland J, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet, 366: 1279–1289, 2005
Meier C, Kraenzelin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med, 168: 820–825, 2008
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidylpeptidase-4 inhibitors in type 2 diabetes. Lancet, 368: 1696–1705, 2006
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lechleitner, M. Oral antidiabetic drug therapy in type 2 diabetes mellitus – focus on elderly patients. Wien Med Wochenschr 161, 297–299 (2011). https://doi.org/10.1007/s10354-011-0914-6
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-011-0914-6